Quarterly ResultJul 30, 2026, 07:21 AM
HUTCHMED H1 Revenue $278.3M; China Sales Up 40%+; Pipeline Advances
AI Summary
HUTCHMED reported H1 2026 financial results with total revenue of $278.3 million. Oncology/Immunology consolidated revenue increased 13% to $162.3 million, driven by strong China product sales recovery, with ELUNATE® and SULANDA® growing over 40% each, and FRUZAQLA® ex-US sales up ~70%. Net income attributable to HUTCHMED was $15.9 million, compared to $455.0 million in H1 2025 which included a significant divestment gain. The company maintained a strong cash balance of $1.37 billion and made significant progress in its ATTC pipeline and regulatory approvals.
Key Highlights
- Total revenue was $278.3 million for H1 2026.
- Oncology/Immunology consolidated revenue increased 13% to $162.3 million.
- ELUNATE® in-market sales grew 41% to $60.8 million.
- SULANDA® in-market sales grew 45% to $18.4 million.
- FRUZAQLA® ex-US sales increased ~70% to $68.9 million.
- Net income attributable to HUTCHMED was $15.9 million.
- Cash, cash equivalents, and short-term investments stood at $1.37 billion.
- Full year 2026 Oncology/Immunology revenue guidance reiterated at $330M-$450M.
Price Impact
More from HCM